Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Stéphane J. Mouly
 -- 1623 2022-07-21 16:36:53 |
2 format correct
Vivi Li
+ 34 word(s) 1657 2022-07-22 05:32:09 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Trimboli, P.;  Mouly, S. Two Non-Tablet Oral Formulations of L-Thyroxine. Encyclopedia. Available online: https://encyclopedia.pub/entry/25405 (accessed on 30 June 2024).
Trimboli P,  Mouly S. Two Non-Tablet Oral Formulations of L-Thyroxine. Encyclopedia. Available at: https://encyclopedia.pub/entry/25405. Accessed June 30, 2024.
Trimboli, Pierpaolo, Stéphane Mouly. "Two Non-Tablet Oral Formulations of L-Thyroxine" Encyclopedia, https://encyclopedia.pub/entry/25405 (accessed June 30, 2024).
Trimboli, P., & Mouly, S. (2022, July 21). Two Non-Tablet Oral Formulations of L-Thyroxine. In Encyclopedia. https://encyclopedia.pub/entry/25405
Trimboli, Pierpaolo and Stéphane Mouly. "Two Non-Tablet Oral Formulations of L-Thyroxine." Encyclopedia. Web. 21 July, 2022.
Two Non-Tablet Oral Formulations of L-Thyroxine
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm11123479

Increased knowledge of the pharmacokinetic characteristics of orally administered levothyroxine (L-T4) has improved individualization of dosing regimens. However, up to 40–45% of patients, depending on the leading cause of hypothyroidism, are still over- or, more often, undertreated. Unintentional non-adherence to L-T4 replacement therapy includes all situations of unintended drug–drug and drug–food interactions as well as fasting conditions that are not necessarily respected by patients. The non-tablet L-T4 soft-gel capsules and solution have proven bioequivalence with the usual L-T4 tablet Princeps and generic formulations. Clinical studies have suggested higher performance of non-tablet formulations than tablet in those patients with suboptimal adherence. 

levothyroxine hypothyroidism soft-gel capsule oral solution pharmacokinetics drug–food interactions gastrointestinal conditions switch

1. Introduction

Thyroid hormones play a critical role in the human body and, as such, if such hormones are absent, they must be replaced. Levothyroxine (L-T4) is the recommended replacement thyroid hormone for both primary and central hypothyroidism. Since the 1970s, most hypothyroid subjects worldwide have been treated with the usual oral tablet L-T4; thus, it is in the first decile of most prescribed medications in Western countries [1][2]. Levothyroxine is a critical-dose drug since even slight variations in blood concentration may determine treatment failure (i.e., incomplete replacement or iatrogenic thyrotoxicosis). Then, individualized L-T4 treatment is required and a close clinical follow-up to avoid under- and overtreatment of patients.
The daily dose of L-T4 depends on the leading cause of hypothyroidism (mostly primary hypothyroidism) as well as on several potential determinants, mainly patients’ lean body mass, which is not routinely measured in clinical practice, and the therapeutic goal (i.e., replacement or Thyreo-Stimulating Hormone (TSH)-suppressive therapy in thyroid cancer patients, when needed). Recent improvement in knowledge concerning the pharmacokinetic characteristics of orally administered L-T4 has improved individualization of dosing regimens. However, up to 40–45% of patients, depending on the leading cause of hypothyroidism, are still over- or, more often, undertreated [3], and nonadherence only accounts for less than 17% of the cause of poorly targeted dosing regimens [1][2]. Unintentional non-adherence to L-T4 replacement therapy includes all situations of unintended drug–drug and drug–food interactions, as well as fasting conditions that are not necessarily respected by patients despite it being well known that undergoing L-T4 replacement therapy in fasting conditions improves intestinal absorption of the active ingredient [4]. Besides these causes of increased doses of L-T4, some conditions and disorders may enhance daily L-T4 requirement by affecting its intestinal absorption, including celiac disease, lactose intolerance and infections, especially Giardia intestinalis infection [2][4]. In this specific context, it has to be remarked that the overall information concerning those factors with the potential to affect L-T4 absorption refers only to tablet formulation. Indeed, this is the reason why new non-tablet formulations of L-T4 were introduced some years ago. Furthermore, numerous studies have been published during the last decade in this field and reported that hypothyroid patients with not-on-target TSH for tablet L-T4 can experience optimal (or at least improved) thyroid hormonal balance after switching to liquid or soft-gel L-T4 formulation despite an unchanged dose. In contrast, to the best of researchers' knowledge, no papers have recorded an improvement of control of hypothyroidism when a patient switches from soft gel or liquid to tablet L-T4.
Alongside this increasing information, whether such improvement in dosing regimens and pharmacokinetic stability is or is not associated with substantial improvement in clinical symptoms and number and frequency of both over- and undertreated patients remains debated. In this regard, the current entry was designed to summarize pharmacokinetics, drug and food interactions and clinical data focusing on two new L-T4 preparations, i.e., liquid and soft-gel capsule, in healthy volunteers and patients with primary hypothyroidism.

2. Bioequivalence Studies with Soft-Gel Capsule and Oral Liquid Formulation

Because levothyroxine pharmacokinetics is highly variable due to the influence of several physiological (e.g., old age, pregnancy) and pathological (liver or kidney impairment, morbid obesity, gastrointestinal disorders) conditions, as well as numerous drug–drug and drug–food interactions, reaching bioequivalence between Princeps and the numerous formulations currently marketed may appear as a challenge. Indeed, results of the pharmacokinetic studies involving L-T4 need to be carefully interpreted, considering baseline hormone concentration and central nervous system feedback mechanisms. In this regard, pharmacokinetic studies have focused on L-T4 serum concentrations rather than TSH, the target biomarker in clinical practice.
Numerous studies, most of them conducted in healthy euthyroid subjects, have confirmed bioequivalence between, separately, the classical sodium levothyroxine formulation and L-T4 soft-gel capsule or the latter and the solution. Overall rate and extent of exposure, as well as elimination half-life (ranging from 6 and up to 9 days) were not statistically different among the preparations but faster (approximately 30 min earlier) onset of absorption was noted with the new oral liquid L-T4 versus gel caps and the Princeps tablet formulation in a few studies [5]. Low- (50 μg), medium- (100 μg) and high (200 μg)-strength soft-gel capsules of L-T4 were bioequivalent to the European reference tablet, showing proportionality, at a dosage of 600 μg in healthy volunteers, the latter dosage being required by many agencies in order to achieve L-T4 concentrations sufficiently above the endogenous base [6]. In the study, it was interesting to note that the 90% confidence interval (CI) to demonstrate bioequivalence was set at 80–125%, and that the authors observed as much as 15% intra-individual variability in their study enrolling only healthy subjects despite stable L-T3 concentrations and similar tolerance between the respective formulations [6]. Two distinct soft-gel capsules (the “old” one and the “new” one manufactured using the new Food & Drug Administration Potency guidelines) were shown to be bioequivalent with each other and with the American tablet formulation (Synthroid), using bioequivalence 90% with a confidence interval of 80–125% for mean ratio of the serum L-T4 systemic exposure [7]. Finally, bioequivalence, as assessed by using the 90% CI for mean ratio of the systemic exposure (i.e., Cmax and AUC0-48) was also confirmed between the two new oral formulations, oral solution and soft-gel capsules, in a recent crossover study conducted in healthy subjects taking a single oral dose of 4 × 150 μg with or without water and using current European Medicine Agency (EMA) prespecified bounds of 90.00 to 111%, as recently required for bioequivalence studies [8].

3. The Oral Solution and Soft-Gel Capsule Formulations Display Better Pharmacokinetic Profiles than the Usual Tablets of Levothyroxine in the Case of Drug–Drug or Drug–Food Interactions

It is known that several factors can interfere with intestinal absorption of L-T4, i.e., food ingestion, dietary fiber, coffee, breakfast beverages and drugs. Numerous drug–drug and drug–food interactions with L-T4 tablets have been identified and reports on them have been published over the past 30 years, as summarized in Table 1 [9][10]. Most of these drug–drug and drug–food interactions led to L-T4 intestinal malabsorption and further increase in TSH level, consistent with under-substitution despite stable dosage of L-T4. One of the most clinically relevant drug–drug interactions in this setting involves proton-pump inhibitors, which induce clinically significant L-T4 malabsorption by modifying gastric pH [11][12]. In a retrospective real-world evidence study in primary care, drug–drug interactions involving proton-pump inhibitors accounted for 88% of all drug–drug interactions reported with levothyroxine tablets, oral solution or soft-gel capsules [13]. Such interactions with proton-pump inhibitors may be solved by switching from the Princeps levothyroxine tablet to the new soft-gel capsule, as observed in a recent case report of a woman in whom an absorption test displayed a 48% increase in systemic exposure of L-T4 along with faster intestinal absorption [11]. In addition, despite that TSH variation in serum did not differ significantly between the tablet formulation and the, soft-gel capsule and oral solution, separately, the latter allowed more a stable dosing regimen and less dose adjustment, consistent with a more stable pharmacokinetic profile in the case of drug–drug interactions in the clinical setting [13]. In another study conducted in healthy volunteers, bioequivalence between L-T4 tablets and soft-gel capsules was lost when taken with esomeprazole, with a 16% decrease in the peak serum concentration and systemic exposure of L-T4 tablets as compared to the soft-gel capsules [12]. Calcium salt supplementation, especially in postmenopausal women, may increase the risk of L-T4 malabsorption and suboptimal TSH balance in hypothyroid patients. Despite that this drug–drug interaction may prevent delayed calcium salt ingestion, it is not always satisfactory as compared to switching from the tablet to the new oral solution or L-T4 soft-gel capsules, as recently observed in a clinical study involving 50 hypothyroid postmenopausal women taking L-T4 tablet therapy [14].
Table 1. Impact of drug and food on levothyroxine absorption [9][10].
Interactions with Drugs Interactions with Food
  • Acid suppression therapies (proton-pump inhibitors, H2 receptor antagonists, sucralfate)
  • β-blockers
  • Bile acid sequestrants (cholestyramine, colestipol and colesevelam)
  • Calcium salts (carbonate, citrate, and acetate)
  • Cation exchange resins
  • Charcoal
  • Chromium
  • Ciprofloxacin
  • Ferrous sulfate
  • Lanthanum
  • Multivitamins (containing ferrous sulfate or calcium carbonate)
  • Oral bisphosphonates
  • Orlistat
  • Phosphate binders (sevelamer, aluminum hydroxide)
  • Polystyrene sulfonate
  • Rifampicin
  • Raloxifene
  • Simethicone
  • Tricyclic antidepressant
  • Coffee
  • Fiber
  • Grapefruit
  • Ingestion with a meal
  • Papaya
  • Soybeans and soy
Current guidelines recommend taking L-T4 in fasting conditions, challenging adherence to medical recommendations, especially regarding other medications; a significant number of patients have suboptimal compliance with L-T4 ingestion as they have to postpone breakfast by at least 30 min [15]. The TICO randomized, double-blind, placebo-controlled crossover trial suggested that liquid L-T4 solution with ethanol should be ingested directly with or 30 min before breakfast with no statistical difference in TSH, free T3 and free T4 levels, thus potentially improving therapeutic compliance. The use of L-T4 liquid formulation without ethanol concomitantly with breakfast, however, remains off-label. This observation is of remarkable clinical relevance since suboptimal adherence to L-T4 therapy is more likely to cause TSH variation over time [15][16]. Patients undergoing treatment with L-T4 are usually asked to ingest the drug in the morning, at least 30 min before having breakfast, because a significantly decreased L-T4 absorption was reported with food when patients are treated with the usual tablet [17][18]. However, oral solution without ethanol should still be preferred in patients in whom even small changes in the free fraction of T3 or T4 may be associated with unwanted side effects, including patients with heart condition or thyroidectomy following thyroid cancer [19].

References

  1. Benvenga, S. Liquid and soft gel capsules of L-thyroxine results lower serum thyrotropin levels more than tablet formulations in hypothyroid patients. J. Clin. Translat. Endocrinol. 2019, 18, 100204.
  2. Virili, C.; Trimboli, P.; Centanni, M. Novel thyroxine formulations: A further step toward precision medicine. Endocrine 2019, 66, 87–94.
  3. Eligar, V.; Taylor, P.N.; Okosieme, O.E.; Leese, G.P.; Dayan, C.M. Thyroxine replacement: A clinical endocrinologist’s viewpoint. Ann. Clin. Biochem. 2016, 53, 421–433.
  4. Visser, W.E.; Friesema, E.C.; Visser, T.J. Minireview: Thyroid hormone transporters: The knowns and the unknowns. Mol. Endocrinol. 2011, 25, 1–14.
  5. Yue, C.S.; Scarsi, C.; Ducharme, P. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung 2012, 62, 631–636.
  6. Al-Numani, D.; Scarsi, C.; Ducharme, M.P. Levothyroxine soft capsules demonstrate bioequivalent pharmacokinetic exposure with the European reference tablets in healthy volunteers under fasting conditions. Int. J. Clin. Pharmacol. Ther. 2016, 54, 135–143.
  7. Colucci, P.; D’Angelo, P.; Mautone, G.; Scarsi, C.; Ducharme, M.P. Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions. Ther. Drug Monit. 2011, 33, 355–361.
  8. Tanguay, M.; Girard, J.; Scarsi, C.; Mautone, G.; Larouche, R. Pharmacokinetics and comparative bioavailability of a levothyroxine sodium oral solution and soft capsule. Clin. Pharmacol. Drug Dev. 2019, 8, 521–528.
  9. Colucci, P.; Seng Yue, C.; Ducharme, M.; Benvenga, S. A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur. Endocrinol. 2013, 9, 40–47.
  10. Castellana, M.; Castellana, C.; Giovanella, L.; Trimboli, P. Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: Should this formulation still be considered as the first-line therapy? Endocrine 2020, 67, 281–290.
  11. Vita, R.; Benvenga, S. Tablet Levothyroxine (L-T4) malabsorption induced by proton pump inhibitor: A problem that was solved by switching to L-T4 in soft gel capsules. Endoc Pract 2014, 20, e38–e41.
  12. Yue, C.S.; Benvenga, S.; Scarsi, C.; Loprete, L.; Ducharme, M.P. When bioequivalence in healthy volunteers may not translate to bioequivalence in patients: Differential effects of increased gastric pH on the pharmacokinetics of levothyroxine capsules and tablets. J. Pharm. Pharm. Sci. 2015, 18, 844–855.
  13. Gugliemi, V.; Bellia, A.; Bianchini, E.; Medea, G.; Cricelli, I.; Sbraccia, P.; Lauro, D.; Cricelli, C.; Lapi, F. Drug interactions in users of tablet vs. oral liquid levothyroxine formulations: A real-world evidence study in primary care. Endocrine 2018, 59, 585–592.
  14. Morini, E.; Catalano, A.; Lasco, A.; Morabito, N.; Benvenga, S. L-thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or soft gel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia. Endocrine 2019, 65, 569–579.
  15. Cappelli, C.; Pirola, I.; Daffini, L.; Formenti, A.; Lacobello, C.; Cristiano, A.; Gandossi, A.; Agabiti Rosei, E.; Castellano, M. A double-blind placebo-controlled trial of liquid thyroxine ingested at breakfast: Results of the TICO Study. Thyroid 2016, 26, 197–203.
  16. Trimboli, P.; Scappaticcio, L.; De Bellis, A.; Maiorino, M.I.; Knappe, L.; Esposito, K.; Bellastella, G.; Giovanella, L. Different formulations of levothyroxine for treating hypothyroidism: A Real-Life study. Int J. Endocrinol. 2020, 2020, 4524759.
  17. Wenzel, K.W.; Kirschsieper, H.E. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 1977, 26, 1–8.
  18. Lamson, M.J.; Pamplin, C.L.; Rolleri, R.L. Quantitation of a substantial reduction in levothyroxine (T4) absorption by food. Thyroid 2004, 14, 876.
  19. Cappelli, C.; Pirola, I.; Gandossi, E.; Cristiano, A.; Daffini, L.; Agosti, B.; Casella, C.; Castellano, M. Thyroid hormone profile in patients ingesting soft gel capsule or liquid levothyroxine formulations with breakfast. Int. J. Endocrinol. 2016, 2016, 9043450.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Pharmacology & Pharmacy
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Pierpaolo Trimboli
,
Stéphane Mouly
View Times: 389
Revisions: 2 times (View History)
Update Date: 22 Jul 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback